Despite the predominantly nodal CLL progression, multicolor flow cytometry and NGS-based blood monitoring of lymphoma clones over time (IGH and KRAS) provided a liquid biopsy window into disease dynamics showing a continuous increase of the MBL/CLL clone from the start of the dual BRAFi/MEKi treatment followed by rapid decline of the CLL clone upon withdrawal of the BRAFi (Figure 1B). This evidence concerns the gene KRAS and lymphoma.